BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lucid Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.


8/17/2012 9:55:24 AM

ROCHESTER, N.Y., Aug. 16, 2012 /PRNewswire/ -- Lucid, Inc. announced today that, effective immediately, it is operating under a new company name, Caliber Imaging & Diagnostics, Inc., or Caliber ID. The new name reflects the company's commitment to innovating and delivering the highest caliber identification tools for accurate, rapid diagnosis to assist in the fight against skin cancer and other diseases.

(Logo: http://photos.prnewswire.com/prnh/20120816/NY57816LOGO )

Caliber ID has created an entirely new class of tools enabling physicians to image and diagnose skin disease in real time without a biopsy. These devices using Caliber ID's reflectance confocal microscopy (RCM) technology allow physicians to detect and diagnose skin disease, including basal cell carcinoma, melanoma, and inflammatory and pigmentary disorders. Caliber ID's RCM technology offers physicians the option to non-invasively diagnose, monitor and follow-up the non-invasive treatment of basal cell carcinoma, the most commonly diagnosed cancer in mankind, and includes the capacity to visualize the margins of the disease prior to surgery, improving patient outcomes.

"This technology is clearly a clinically-relevant diagnostic tool," notes Dr. Martin C. Mihm Jr., Associate Physician at Brigham and Women's Hospital, Clinical Professor of Pathology (Dermatology) at Harvard Medical School and chair of the Caliber ID scientific advisory board. "The clinical data indicates that this suite of technologies can substantially reduce the need to biopsy healthy tissue by giving physicians the ability to noninvasively image and diagnose skin cancers and other skin disease. In the hands of an experienced confocal user, resolution and accuracy is comparable to that of traditional histology."

The Company has developed an integrated platform of tools, including the Caliber ID VivaScope® 1500 and VivaScope® 3000 imagers along with Caliber ID's telepathology service that can be used by doctors, surgeons, and research laboratories. Its tools are already in use by doctors and researchers in major academic hospitals including Memorial Sloan Kettering (New York, NY), Brigham and Women's Hospital (Boston, MA), the Charite Hospital in Berlin (GERMANY) and the Melanoma Institute Australia (Sydney, AUSTRALIA).

About Caliber ID

Caliber ID's platform of products offer increased productivity from the doctor's office to the surgeon's operating room. Today, the future of skin cancer diagnosis is here: an integrated platform of tools and technology for accurate diagnoses quickly and routinely. Caliber ID products provide precise accuracy, consistent reliability, and online backup that all combine to lead to life-saving early diagnosis. Wherever you are in the continuum of skin imaging and diagnosis, this is not just best in class. This is a new class. For more information about Caliber ID and its products, please visit www.caliberid.com

VivaScope® is a registered trademarks of Caliber ID.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed with the SEC.

Contact:
Caliber Imaging & Diagnostics, Inc.
Rich Pulsifer
Phone: (585) 758-2813
Fax: (585) 239-9806

SOURCE Caliber Imaging & Diagnostics, Inc.



Read at BioSpace.com

Lucid
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES